GGrantIndex
Sort

51,593 grants matching hepatitis

6B:A Pharmacokinetic & Pharmacodynamic Study of an Antibody-based Vaginal Microb

$552,301
Susan Cu-Uvin · Boston University Medical Campus · U19 · FY2014 · AI

Immunoregulation in Schistosomiasis

$552,296
Miguel J. Stadecker · Tufts University Boston · R01 · FY2020 · AI

Immunoregulation in Schistosomiasis

$552,296
Miguel J. Stadecker · Tufts University Boston · R01 · FY2019 · AI

Immunoregulation in Schistosomiasis

$552,296
Miguel J. Stadecker · Tufts University Boston · R01 · FY2018 · AI

Immunoregulation in Schistosomiasis

$552,296
Miguel J. Stadecker · Tufts University Boston · R01 · FY2016 · AI

Immunoregulation in Schistosomiasis

$552,296
Miguel J. Stadecker · Tufts University Boston · R01 · FY2017 · AI

Antiretroviral Therapy and the Hepatitis C Virus

$552,261
Kenneth E Sherman · University Of Cincinnati · R01 · FY2010 · AI

Genetic risk factors for alcoholic cirrhosis - genome-wide case-control study

$552,182
Timothy Ross Morgan · Southern California Inst For Res/Educ · U01 · FY2012 · AA

Prenatal Anxiety and its Effects on Child Development

$552,164
Thomas G O'Connor · University Of Rochester · R01 · FY2008 · MH

HCV Infection--Risk Factors for Progression

$552,164
Harvard University (Sch Of Public Hlth) · R01 · FY2003 · CA

Mid Southern Primary Care Networks Node

$552,141
Li-Tzy T Wu · Duke University · UG1 · FY2019 · DA

Preclinical studies of a heroin/morphine vaccine for opiate addiction

$552,119
Paul Pentel · Hennepin Healthcare Research Institute · R01 · FY2013 · DA

Effects of State Laws to Reduce Opioid Diversion on Transitions to Injection Drug Use and HIV/HCV Transmission

$552,095
Julia B Dickson-Gomez · Medical College Of Wisconsin · R01 · FY2020 · DA

Exploring the Fetal Origins Hypothesis in Diverse Youth

$552,056
Dana Dabelea · University Of Colorado Denver · R01 · FY2014 · DK

Rational development of anti-Trypanosoma cruzi drugs

$552,036
Frederick Simmons Buckner · University Of Washington · R01 · FY2012 · AI

Disulfiram Interactions With HIV Medications: Clinical Implications

$551,992
Elinore F. McCance-Katz · University Of California, San Francisco · R01 · FY2008 · DA

Optimizing Lung Cancer Treatment in HIV Infected Persons

$551,979
Keith Magnus Sigel · Icahn School Of Medicine At Mount Sinai · R01 · FY2018 · CA

Novel therapeutic approaches to treating chronic hepatitis B virus infection

$551,970
Lishan Su · Univ Of North Carolina Chapel Hill · R01 · FY2015 · DK

Bile acids and insulin sensitivity

$551,959
Rebecca Anne Haeusler · Columbia University Health Sciences · R01 · FY2019 · DK

Toxic lipid intermediate accumulation and cobalamin depletion promote AHR-mediated hepatotoxicity and the progression of non-alcoholic fatty liver disease (NAFLD)-like pathologies

$551,938
Timothy R Zacharewski · Michigan State University · R01 · FY2025 · ES

Life Course Investigation of People Who Inject Drugs

$551,935
Robert E Booth · University Of Colorado Denver · R01 · FY2017 · DA

HCV TRANSMISSION: SEX, VIOLENCE ALCOHOL &DRUG USE

$551,910
Pacific Institute For Res And Evaluation · R01 · FY2001 · DA

RECK regulation of NASH and fibrosis

$551,909
Randy Scott Rector · University Of Missouri-Columbia · R01 · FY2023 · DK

RECK regulation of NASH and fibrosis

$551,909
Randy Scott Rector · University Of Missouri-Columbia · R01 · FY2022 · DK

RECK regulation of NASH and fibrosis

$551,909
Randy Scott Rector · University Of Missouri-Columbia · R01 · FY2025 · DK